OPN-662

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

130

Last Updated

2 months ago

Participating Centers

There are 10 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
OPN-6602 is a type of drug called a bromodomain inhibitor that targets the p300 and CREB-binding protein found on some cancer cells. This drug may work by blocking cancer cells from growing and multiplying.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Dose Escalation

Accepting patients

Dose Escalation: OPN-6602 + Dexamethasone

Not yet accepting

Dose Expansion

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.